The Microbiome Therapeutics Market size was valued at USD 94.21 million in 2022 and is expected to reach at USD 1039 million by 2030, and grow at a CAGR of 35 % over the forecast period of 2023-2030.
According to our analysis there has been rise in the diseases related to the immunity, metabolism, the disease which attacks the immunity are to be considered very dangerous in terms of adverse effect on long term health condition, because immunity is the factor which protects the body from the virus and infections, The microbes are set of virus, bacteria, fungi and their genes which are present in our body the major function of the microbiome is to protect our health from harmful bacteria, also it helps in digestion and according to our sources it also helps in creating a strong immune system, the microbes are majorly present near the intestines where the segregation and the synthesizing of the toxic food and proteins is been done, also the microbes are present all over the body. The microbiome of different for every person but the functionality is the same, the major importance of the microbiome in our body is for the immune system.
The microbiome can be consumed form the foods which are high in microbiome or by probiotics, there has been a huge increase in the sale of the probiotics compare to the sales data of 2015 though it also has negative side effects which are related to the over consumption. The concerning factors about the imbalance of the microbiome in our body is that it leads to several diseases which includes cancer, type 2 diabetes, obesity intestinal bowel disease and many more the rising environmental concerns are leading to the contribution of the rise in the microbiome and also the lifestyle of the people in the developed and the emerging countries, the research has assured that the major reason why the imbalance in the human microbiome is been observed is because of the poor sleep patterns, excessive drinking and smoking, poor diet and so forth this were the micro factors the macro factors include the environmental conditions which consist of gas chemical and carbon emission which affects the physical health condition of humans and this leads to the negative effect on the microbiome present in body and this is where the demand for the microbiome therapeutics increase there are several initiative taken by the health professionals all around the globe for securing the better treatment for the patient, there has been several trial conducted so that the microbiome can be healed during the early phases in therapeutics the target is mainly the microbiota, the strategy applied includes the addition of the natural organisms, therapeutics payloads and some selective antimicrobials, according to National Institutes of Health (NIH) the rise in the technological advancement in the healthcare industry and the government plans and programs related to the same will be the reason the microbiome therapeutics market will attract good growth during the forecasted period.
The Covid-19 had a negative impact on the microbiome therapeutics market because the major factor which is important for the microbiome therapeutics is the clinical trial, the lockdown rules imposed by the government made it difficult for the health professionals to conduct clinical trials, another insights which we got form some of the key players which state their condition during the covid-19 was lack of support staff as the healthcare industry was busy prioritizing covid patients the lack of the health staffs was experienced and the difficulty in collecting the data through which the clinical trials can be conducted made the situation worse.
The rise in the demand for the microbiome therapeutics.
As we mentioned earlier the external factors and the internal factor has raise the concerns related to the human health which affects the microbiome negatively and this where the demand for the microbiome is increasing because it is obvious the lack of the microbiome in the body results towards several major disease and this is what increase the demand for the microbiome therapeutics and drives the microbiome therapeutics market.
Restrain:
The different nature of human microbiota condition which makes the treatment complex.
Stringent rules and regulations related to the drug approvals.
Opportunity:
The rising clinical trials and the progress related to the cellular autonomous therapeutic.
In the recent times or let’s say during the pandemic itself there has a been a rise in the awareness and implementation related to automation in healthcare, AI, ML and many other technologies the major objective behind the development of the technologies is the goal of reducing human efforts and increase on the efficiency and productivity, the same thing applies for the microbiome therapeutics and this is where the key players are majorly trying to focus also the support from the official government organizations related to the approval related to the drug development will contribute to the growth of the market.
Challenge:
The high cost initiated with the production and the treatment of the microbiome and the lack of development in the emerging countries, also the rise in the global disruption which can have a negative effect on the nations and key players economic conditions which will ultimately affect the growth of the microbiome therapeutics market.
By Type:
FMT
Microbiome Drugs
By Application:
C. difficile
Crohn’s disease
Inflammatory Bowel Disease
Diabetes
Others
.png)
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
south Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Regional Analysis
North America will be dominating the market because of the rising development and the initiatives of the key players to innovate and conduct research for the therapeutics of microbiome, the rising support of the FDA to allow and conduct trials and at the same time approved drugs which will be beneficial for the treatment of the unbalanced microbiome, another key factors which contributes to the growth of the therapeutic market in this region is because of the unhealthy lifestyle of the people living in the developed countries of NA region, for instance U.S. is the country which has the highest number of organization relayed to the microbiome therapeutics.
The major key players are OpenBiome, Seres Therapeutics Inc, 4D Pharma plc, Locus Biosciences, Inc, Enterome SA, Finch Therapeutics group, Inc, Intralytix, Inc, Microbiotica, Second Genome, Rebiotix Inc, Vedanta Bioscience, Inc.
| Report Attributes | Details |
| Market Size in 2022 | US$ 94.21 Mn |
| Market Size by 2030 | US$ 1039 Mn |
| CAGR | CAGR of 35% From 2023 to 2030 |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2020-2021 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (FMT, Microbiome Drugs) • By Application (C. difficile, Crohn’s disease, Inflammatory Bowel Disease, Diabetes, Others) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | OpenBiome, Seres Therapeutics Inc, 4D Pharma plc, Locus Biosciences, Inc, Enterome SA, Finch Therapeutics group, Inc, Intralytix, Inc, Microbiotica, Second Genome, Rebiotix Inc, Vedanta Bioscience, Inc |
| Key Drivers | • The rise in the demand for the microbiome therapeutics. |
| Market Opportunities | • The rising clinical trials and the progress related to the cellular autonomous therapeutic. |
The Microbiome Therapeutics Market size was valued at USD 94.21 million in 2022 and is expected to reach at USD 1403 million by 2030, and grow at a CAGR of 35 % over the forecast period of 2023-2030.
The rise in the demand for the microbiome therapeutics.
The major key players are OpenBiome, Seres Therapeutics Inc, 4D Pharma plc, Locus Biosciences, Inc, Enterome SA, Finch Therapeutics group, Inc, Intralytix, Inc, Microbiotica, Second Genome, Rebiotix Inc, Vedanta Bioscience, Inc
The Covid-19 had a negative impact on the microbiome therapeutics market
North America will be dominating the market because of the rising development and the initiatives of the key players
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 COVID 19 Impact Analysis
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Global Microbiome Therapeutics Market Segmentation, By Type
8.1 FMT
8.2 Microbiome Drugs
9. Global Microbiome Therapeutics Market Segmentation, By Application
9.1 C. difficile
9.2 Crohn’s disease
9.3 Inflammatory Bowel Disease
9.4 Diabetes
9.5 Others
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America Global Microbiome Therapeutics Market by country
10.2.2North America Global Microbiome Therapeutics Market by Type
10.2.3 North America Global Microbiome Therapeutics Market by Application
10.2.4 USA
10.2.4.1 USA Global Microbiome Therapeutics Market by Type
10.2.4.2 USA Global Microbiome Therapeutics Market by Application
10.2.5 Canada
10.2.5.1 Canada Global Microbiome Therapeutics Market by Type
10.2.5.2 Canada Global Microbiome Therapeutics Market by Application
10.2.6 Mexico
10.2.6.1 Mexico Global Microbiome Therapeutics Market by Type
10.2.6.2 Mexico Global Microbiome Therapeutics Market by Application
10.3 Europe
10.3.1 Europe Global Microbiome Therapeutics Market by country
10.3.3.2 Europe Global Microbiome Therapeutics Market by Type
10.3.3 Europe Global Microbiome Therapeutics Market by Application
10.3.4 Germany
10.3.4.1 Germany Global Microbiome Therapeutics Market by Type
10.3.4.2 Germany Global Microbiome Therapeutics Market by Application
10.3.5 UK
10.3.5.1 UK Global Microbiome Therapeutics Market by Type
10.3.5.2 UK Global Microbiome Therapeutics Market by Application
10.3.6 France
10.3.6.1 France Global Microbiome Therapeutics Market by Type
10.3.6.2 France Global Microbiome Therapeutics Market by Application
10.3.7 Italy
10.3.7.1 Italy Global Microbiome Therapeutics Market by Type
10.3.7.2 Italy Global Microbiome Therapeutics Market by Application
10.3.8 Spain
10.3.8.1 Spain Global Microbiome Therapeutics Market by Type
10.3.8.2 Spain Global Microbiome Therapeutics Market by Application
10.3.9 The Netherlands
10.3.9.1 Netherlands Global Microbiome Therapeutics Market by Type
10.3.9.2 Netherlands Global Microbiome Therapeutics Market by Application
10.3.10 Rest of Europe
10.3.10.1 Rest of Europe Global Microbiome Therapeutics Market by Type
10.3.10.2 Rest of Europe Global Microbiome Therapeutics Market by Application
10.4 Asia-Pacific
10.4.1 Asia Pacific Global Microbiome Therapeutics Market by country
10.4.2 Asia Pacific Global Microbiome Therapeutics Market by Type
10.4.3 Asia Pacific Global Microbiome Therapeutics Market by Application
10.4.4 Japan
10.4.4.1 Japan Global Microbiome Therapeutics Market by Type
10.4.4.2 Japan Global Microbiome Therapeutics Market by Application
10.4.5 South Korea
10.4.5.1 South Korea Global Microbiome Therapeutics Market by Type
10.4.5.2 South Korea Global Microbiome Therapeutics Market by Application
10.4.6 China
10.4.6.1 China Global Microbiome Therapeutics Market by Type
10.4.6.2 China Global Microbiome Therapeutics Market by Application
10.4.7 India
10.4.7.1 India Global Microbiome Therapeutics Market by Type
10.4.7.2 India Global Microbiome Therapeutics Market by Application
10.4.8 Australia
10.4.8.1 Australia Global Microbiome Therapeutics Market by Type
10.4.8.2 Australia Global Microbiome Therapeutics Market by Application
10.4.9 Rest of Asia-Pacific
10.4.9.1 APAC Global Microbiome Therapeutics Market by Type
10.4.9.2 APAC Global Microbiome Therapeutics Market by Application
10.5 The Middle East & Africa
10.5.1 The Middle East & Africa Global Microbiome Therapeutics Market by country
10.5.2 The Middle East & Africa Global Microbiome Therapeutics Market by Type
10.5.3 The Middle East & Africa Global Microbiome Therapeutics Market by Application
10.5.4 Israel
10.5.4.1 Israel Global Microbiome Therapeutics Market by Type
10.5.4.2 Israel Global Microbiome Therapeutics Market by Application
10.5.5 UAE
10.5.5.1 UAE Global Microbiome Therapeutics Market by Type
10.5.5.2 UAE Global Microbiome Therapeutics Market by Application
10.5.6 South Africa
10.5.6.1 South Africa Global Microbiome Therapeutics Market by Type
10.5.6.2 South Africa Global Microbiome Therapeutics Market by Application
10.5.7 Rest of Middle East & Africa
10.5.7.1 Rest of Middle East & Asia Global Microbiome Therapeutics Market by Type
10.5.7.2 Rest of Middle East & Asia Global Microbiome Therapeutics Market by Application
10.6 Latin America
10.6.1 Latin America Global Microbiome Therapeutics Market by country
10.6.2 Latin America Global Microbiome Therapeutics Market by Type
10.6.3 Latin America Global Microbiome Therapeutics Market by Application
10.6.4 Brazil
10.6.4.1 Brazil Global Microbiome Therapeutics Market by Type
10.6.4.2 Brazil Africa Global Microbiome Therapeutics Market by Application
10.6.5 Argentina
10.6.5.1 Argentina Global Microbiome Therapeutics Market by Type
10.6.5.2 Argentina Global Microbiome Therapeutics Market by Application
10.6.6 Rest of Latin America
10.6.6.1 Rest of Latin America Global Microbiome Therapeutics Market by Type
10.6.6.2 Rest of Latin America Global Microbiome Therapeutics Market by Application
11. Company profile
11.1 OpenBiome
11.1.1 Market Overview
11.1.2 Financials
11.1.3 Treatment/Services/Offerings
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 Seres Therapeutics Inc
11.2.1 Market Overview
11.2.2 Financials
11.2.3 Treatment/Services/Offerings
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 4D Pharma plc
11.3.1 Market Overview
11.3.2 Financials
11.3.3 Treatment/Services/Offerings
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Locus Biosciences, Inc
11.4.1 Market Overview
11.4.2 Financials
11.4.3 Treatment/Services/Offerings
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Enterome SA
11.5.1 Market Overview
11.5.2 Financials
11.5.3 Treatment/Services/Offerings
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Finch Therapeutics
11.6.1 Market Overview
11.6.2 Financials
11.6.3 Treatment/Services/Offerings
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 Intralytix, Inc
11.7.1 Market Overview
11.7.2 Financials
11.7.3 Treatment/Services/Offerings
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 Microbiotica
11.8.1 Market Overview
11.8.2 Financials
11.8.3 Treatment/Services/Offerings
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Second Genome
11.9.1 Market Overview
11.9.2 Financials
11.9.3 Treatment/Services/Offerings
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 Rebiotix, Inc
11.10.1 Market Overview
11.10.2 Financials
11.10.3 Treatment/Services/Offerings
11.10.4 SWOT Analysis
11.10.5 The SNS View
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments
13. Used Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
In 2022, The Prescription Drugs Market size amounted to USD 1156.57 Billion & is estimated to reach USD 2254.28 Billion by 2030 and increase at a compound annual growth rate of 8.7% between 2023 and 2030.
The Hospital Information System Market Size was valued at USD 64.13 billion in 2022, and is expected to reach USD 102.21 billion by 2030, and grow at a CAGR of 6% over the forecast period 2023-2030.
The Virtual Fitness Market size was valued at USD 20.54 billion in 2023 and is expected to reach approx. USD 137.25 billion by 2031, and grow at a CAGR of 26.81% over the forecast period of 2024-2031.
The Cell & Gene Therapy Manufacturing Services Market Size was valued at USD 6.1 billion in 2023 and is expected to reach USD 38.9 billion by 2031 and grow at a CAGR of 22.3% over the forecast period 2024-2031.
The Cell Separation Market size was estimated USD 8.6 billion in 2022 and is expected to reach USD 24.02 billion by 2030 at a CAGR of 13.7% during the forecast period of 2023-2030.
The Healthcare Payer Services Market Size was valued at USD 62.67 billion in 2022 and is expected to reach USD 111.7 billion by 2030 and grow at a CAGR of 7.5% over the forecast period 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
